SCHEMBL2547692

SCHEMBL2547692

[CH2]C1CC=CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15865212 0.62
SCHEMBL12150170 0.62
SCHEMBL10713533 0.62
SCHEMBL14327500 0.62
SCHEMBL8267240 0.62
SCHEMBL11751205 0.62
SCHEMBL9609373 0.62
SCHEMBL6656462 0.62
SCHEMBL13617273 0.62
SCHEMBL1869500 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107382916-A The high purity synthetic process of 3 tetrahydrofurfuryl carbinols 成都化润药业有限公司 2017-11-24 CN claimed
US-8778958-B2 Synthesis of metabolically stable agents for alcohol and drug abuse HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2014-07-15 US claimed
US-20110263630-A1 SYNTHESIS OF METABOLICALLY STABLE AGENTS FOR ALCOHOL AND DRUG ABUSE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2011-10-27 US claimed
WO-2023147312-A1 AMPK AGONISTS AND METHODS OF USE THEREOF EVVIA THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
EP-3131897-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2022-06-15 EP disclosed
EP-3131896-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2019-01-30 EP disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-9969724-B2 Factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2018-05-15 US disclosed
EP-2789607-B1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2018-02-07 EP disclosed
US-9808445-B2 Factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-07 US disclosed
US-20170129880-A1 FACTOR IXa INHIBITORS MERCK SHARP & DOHME LLC 2017-05-11 US disclosed
WO-2003011885-A1 NON-NATURAL CARBON-LINKED NUCLEOTIDES AND DINUCLEOTIDES CELLTECH R & D LIMITED (GB) 2003-02-13 WO disclosed
US-6472345-B2 TITANIUM HALIDES, SULFONATES OR DIOLATES SOLVIAS AG (CH) 2002-10-29 US disclosed
WO-2002062816-A1 NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES CELLTECH R & D LIMITED (GB) 2002-08-15 WO disclosed
EP-1187798-A1 PRODUCTION OF OPTICALLY ACTIVE $g(a)-HYDROXYACETALS Solvias AG (CH) 2002-03-20 EP disclosed
US-20020026067-A1 Catalytic halogenation of activated methylene and methine compounds SOLVIAS AG (CH) 2002-02-28 US disclosed
EP-1151980-A1 Catalytic halogenation of activated methylene and methine compound Solvias AG (CH) 2001-11-07 EP disclosed
US-20010037042-A1 Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds SOLVIAS AG (CH) 2001-11-01 US disclosed
EP-1132361-A1 Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds Solvias AG (CH) 2001-09-12 EP disclosed
WO-2001000545-A1 PRODUCTION OF OPTICALLY ACTIVE α-HYDROXYACETALS SOLVIAS AG (CH) 2001-01-04 WO disclosed